ADAMTS7
A disintegrin and metalloproteinase with thrombospondin motifs 7 (ADAMTS7) is an
Structure
Gene
The ADAMTS7 gene resides on chromosome 15 at the band 15q24.2 and contains 25 exons.[1]
Protein
This 1686-
Function
ADAMTS7 was identified in a yeast two-hybrid screen using epidermal growth factor (EGF) domain of COMP as the bait. As a metalloproteinase, ADAMTS7 utilizes Zn2+ to catalyze its proteolytic function for COMP degradation.[3]
In vascular
Clinical Significance
A negative correlation between the expression levels of specific miRNAs and ADAMTS7 is observed in normal tissues but not in disease tissues, implying an altered miRNA-target interaction in the disease state. Accordingly, expression profiles of these miRNAs and ADAMTS7 may be useful diagnostic tools to differentiate cancer and lichen planus from normal tissues.[11] ADAMTS7 has also been identified as a putative oncogene and reported to be mutated exclusively in Asians, which may have implications for the prevention and treatment of hepatocellular carcinoma.[4] In addition, ADAMTS7 plays a crucial role in the pathogenesis of arthritis.[5] For example, the FGF2/p65/miR-105/Runx2/ADAMTS axis is reportedly involved in osteoarthritis (OA) pathogenesis.[12] Specifically, ADAMTS7 forms a positive feedback loop with tumour necrosis factor (TNF)-α in the pathogenesis of OA.[13]
Clinical Marker
Genome-wide association studies identified ADAMTS7 as a risk locus for coronary artery disease. Studies have been carried on classification of ADAMTS7 binding site, which may serve as the first step toward developing a new therapeutic target for coronary artery disease.[7] Significant associations for coronary artery calcification with SNPs in ADAMTS7 has also been found in Hispanics.[14] Additionally, a multi-locus genetic risk score study based on a combination of 27 loci, including the ADAMTS7 gene, identified individuals at increased risk for both incident and recurrent coronary artery disease events, as well as an enhanced clinical benefit from statin therapy. The study was based on a community cohort study (the Malmo Diet and Cancer study) and four additional randomized controlled trials of primary prevention cohorts (JUPITER and ASCOT) and secondary prevention cohorts (CARE and PROVE IT-TIMI 22).[6]
References
- ^ a b "ADAMTS7 ADAM metallopeptidase with thrombospondin type 1 motif 7 [Homo sapiens (human)] - Gene - NCBI". www.ncbi.nlm.nih.gov. Retrieved 2016-10-06.
- ^ "BioGPS - your Gene Portal System". biogps.org. Retrieved 2016-10-06.
- ^ PMID 16585064.
- ^ PMID 27246981.
- ^ PMID 26696755.
- ^ PMID 25748612.
- ^ PMID 26872430.
- ^ a b "ADAMTS7 - A disintegrin and metalloproteinase with thrombospondin motifs 7 precursor - Homo sapiens (Human) - ADAMTS7 gene & protein". www.uniprot.org. Retrieved 2016-10-06.
- PMID 19168437.
- ^ PMID 25712206.
- PMID 27515006.
- S2CID 12969036.
- PMID 23928557.
- S2CID 24394552.